118 related articles for article (PubMed ID: 8962258)
1. Tumors after transplantation: are there associated factors?
Jacobs U; Paar D; Buszello H; Klehr HU
Transplant Proc; 1996 Dec; 28(6):3248. PubMed ID: 8962258
[No Abstract] [Full Text] [Related]
2. Chronic rejection in 500 kidney transplant patients treated with cyclosporine: incidence and risk factors.
Pallardó LM; Sánchez J; Puig N; Sánchez P; Beneyto I; Crespo J; Ros F; Rochera A
Transplant Proc; 1995 Aug; 27(4):2215-6. PubMed ID: 7652778
[No Abstract] [Full Text] [Related]
3. Dilemma: maintenance therapy enhances sclerogenic risk profile.
Jacobs U; Klein B; Miersch WD; Molitor D; Klehr HU
Transplant Proc; 1996 Dec; 28(6):3227-30. PubMed ID: 8962249
[No Abstract] [Full Text] [Related]
4. Sole immunosuppressive maintenance with cyclosporine A after heart transplantation.
Koerner MM; Tenderich G; Mannebach H; zu Knyphausen E; Koertke H; Kleesiek K; Gleichmann U; Meyer H; Koerfer R
Transplant Proc; 1996 Dec; 28(6):3119-21. PubMed ID: 8962209
[No Abstract] [Full Text] [Related]
5. Malignancy under immunosuppressive therapy including cyclosporine.
Ritters B; Grabensee B; Heering P
Transplant Proc; 1994 Oct; 26(5):2656-7. PubMed ID: 7940831
[No Abstract] [Full Text] [Related]
6. Tumors after renal transplantation.
Büyükpamukçu N; Karakayali H; Bilgin N
Transplant Proc; 1996 Aug; 28(4):2317-8. PubMed ID: 8769235
[No Abstract] [Full Text] [Related]
7. Kidney transplant recipients and the incidence of adverse reactions to cyclosporin.
Tolou-Ghamari Z; Palizban AA
Saudi Med J; 2004 Oct; 25(10):1499-500. PubMed ID: 15494834
[No Abstract] [Full Text] [Related]
8. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
[TBL] [Abstract][Full Text] [Related]
9. Non-lymphoid cancer after liver transplantation.
Frezza EE; Fung JJ; van Thiel DH
Hepatogastroenterology; 1997; 44(16):1172-81. PubMed ID: 9261620
[TBL] [Abstract][Full Text] [Related]
10. Does suboptimal immunosuppression contribute to chronic rejection?
Simić S; Djukanović L; Stojković D; Balgojević R; Sinthoić M; Lezaić V; Radivojević D
Transplant Proc; 1995 Feb; 27(1):909-10. PubMed ID: 7879226
[No Abstract] [Full Text] [Related]
11. Kidney transplantation from living donors in Hungary: experience of 22 years.
Perner F; Hidvégi M; Járay J; Alföldy F; Gyódi E; Petrányi G
Transplant Proc; 1996 Dec; 28(6):3584-90. PubMed ID: 8962389
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
13. Incidence and type of malignancies occurring after renal transplantation in conventionally and in cyclosporine-treated recipients: single-center analysis of a 20-year period in 1600 patients.
Hiesse C; Larue JR; Kriaa F; Blanchet P; Bellamy J; Benoit G; Charpentier B
Transplant Proc; 1995 Aug; 27(4):2450-1. PubMed ID: 7652877
[No Abstract] [Full Text] [Related]
14. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M
Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine levels predict the likelihood of rejection after simultaneous pancreas/kidney transplantation.
Dawidson I; Lu C; Ar'Rajab A; Rossi P; Melone D; Wheeler D
Transplant Proc; 1994 Apr; 26(2):534. PubMed ID: 8171540
[No Abstract] [Full Text] [Related]
16. Influence of antilymphocyte globulin upon the incidence of malignancies after kidney transplantation.
Luciani J; Benalia H; Bitker MO; Mouquet C; Chartier-Kastler E; Ourhama S; Jacobs C; Chatelain C; Viars P
Transplant Proc; 1993 Jun; 25(3):2302. PubMed ID: 8516907
[No Abstract] [Full Text] [Related]
17. Development of cancer in renal allograft recipients.
Yokota K; Fukumitsu M; Kuzuhara K; Otsubo O; Tomikawa S; Nagao T; Uchida H; Sato K; Nakayama Y; Endo T
Transplant Proc; 1994 Aug; 26(4):1977-8. PubMed ID: 8066639
[No Abstract] [Full Text] [Related]
18. Clinical immunosuppressive matrix in organ transplantation.
Land W
Transplant Proc; 1994 Oct; 26(5):2479-84. PubMed ID: 7940762
[No Abstract] [Full Text] [Related]
19. Immunosuppression, cancer, and the long-term outcomes after liver transplantation: can we do better?
Abraham JM; Thompson JA
Liver Transpl; 2010 Jul; 16(7):809-11. PubMed ID: 20583078
[No Abstract] [Full Text] [Related]
20. [Magnesium deficiency after kidney transplantation and cyclosporine therapy].
Rob PM
Fortschr Med; 1996 Apr; 114(10):125-6. PubMed ID: 8655118
[No Abstract] [Full Text] [Related]
[Next] [New Search]
